July 7, 2026 — Nanox Imaging Ltd. has announced that data from studies featuring its AI cardiac solution (HealthCCSng) will be presented at the 21st Annual Scientific Meeting of the Society of Cardiovascular Computed Tomography (SCCT), in San Diego, California.
Nanox.AI’s FDA-cleared products analyze routine medical CT scans, performed for any clinical indication, to help identify patients with asymptomatic or undetected findings associated with chronic cardiac, liver and bone conditions, enabling proactive preventive care management:
- AI Cardiac solution (HealthCCSng)
- AI Bone solution (HealthOST)
- AI Liver solution (HealthFLD)
Nanox’s SCCT 2026 data will feature initial findings from the multi-site AI INFORM clinical trial, as well as a separate multi-site analysis of agreement between HealthCCSng and expert visual assessment of coronary artery calcium.
The studies are being presented by members of Brigham and Women’s Hospital, Massachusetts General Hospital, University of Texas Southwestern Medical Center and other medical institutions.
The abstracts include:
-
“Artificial Intelligence Detection Of Incidental Coronary Artery Calcium To Enhance Cardiovascular Disease Prevention: The AI INFORM Trial” (Abstract 614; Daniel M. Huck, MD, MPH; Poster Session 20-Plaque Imaging)
-
“Agreement Between AI-detected Coronary Artery Calcium And Expert Visual Assessment: A Multi-site Analysis” (Abstract 565; Camila V. Blair, MD; Poster Session 16-Non contrast cardiac CT: Coronary calcium).
Nanox.AI also is sponsoring a scientific session, “From Missed Finding to Missed Opportunity: Aortic Valve Calcification on Chest CT,” featuring Ofir Koren, MD, of Cedars-Sinai Medical Center. The session will discuss the clinical significance of aortic valve calcification identified on routine chest CT scans and ongoing research in this area. Any referenced technology is currently under development and is not commercially available or cleared for clinical use.
May 20, 2026 
